eligibility_summary
Eligible: adults 18–75, ECOG 0–1, histologically confirmed pancreatic ductal adenocarcinoma, R0 resected stage I–III, no neoadjuvant therapy, adequate marrow/organ function, contraception, consent, protocol compliant. Exclude: anticancer therapy ≤2 wks, other cancers (unless cured), uncontrolled illness/infection, cardiac/pulmonary/cerebrovascular disease, HIV/HBV/HCV, autoimmune/immunosuppressed, pregnant/lactating, recent vaccines, severe vaccine/product allergy, substance abuse, ≥10% weight loss, safety/compliance risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions and mechanisms: 1) Personalized neoantigen vaccine (cancer vaccine, IV): delivers patient-specific tumor neoantigens to antigen-presenting cells to prime/expand tumor-specific CD8+ and CD4+ T cells. 2) Tislelizumab (anti-PD-1 IgG4 monoclonal antibody, immune checkpoint inhibitor): blocks PD-1 to reverse T-cell exhaustion and restore antitumor effector function. 3) Gemcitabine + capecitabine (antimetabolite chemotherapies): gemcitabine (deoxycytidine analog) inhibits ribonucleotide reductase and incorporates into DNA causing chain termination, capecitabine (prodrug of 5-FU) inhibits thymidylate synthase and RNA/DNA synthesis. Targets: PD-1/PD-L1 axis, dendritic cell antigen presentation, activation of tumor-specific T cells, tumor cell DNA synthesis/replication pathways.